Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) were down 7.5% on Tuesday. The stock traded as low as $22.52 and last traded at $22.3630. 324,665 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 3,468,698 shares. The stock had previously closed at $24.17.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Tango Therapeutics from $46.00 to $47.00 and gave the company an "overweight" rating in a report on Tuesday, November 10th. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a research report on Friday, October 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tango Therapeutics in a research report on Wednesday, November 4th. Jefferies Financial Group reissued a "buy" rating and issued a $65.00 target price on shares of Tango Therapeutics in a research note on Tuesday, November 10th. Finally, HC Wainwright decreased their price objective on Tango Therapeutics from $68.00 to $67.00 and set a "buy" rating on the stock in a report on Tuesday, November 10th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $45.54.
Read Our Latest Analysis on TNGX
Tango Therapeutics Stock Down 7.9%
The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -16.26 and a beta of 1.26. The firm has a 50 day moving average price of $23.56 and a two-hundred day moving average price of $22.86.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Analysts predict that Tango Therapeutics, Inc. will post -1.46 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total transaction of $660,690.00. Following the completion of the transaction, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jessica Newcomb sold 8,200 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total transaction of $198,604.00. Following the sale, the insider directly owned 59,121 shares of the company's stock, valued at $1,431,910.62. The trade was a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 52,231 shares of company stock worth $1,254,029. 6.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Tango Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Tango Therapeutics during the second quarter worth about $388,826,000. Goldman Sachs Group Inc. increased its holdings in shares of Tango Therapeutics by 14.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 11,412,008 shares of the company's stock valued at $284,730,000 after acquiring an additional 1,431,388 shares during the last quarter. TRV GP IV LLC acquired a new stake in shares of Tango Therapeutics during the second quarter worth $120,181,383,000. Jupiter Topco LLC bought a new stake in shares of Tango Therapeutics during the 2nd quarter valued at about $157,989,000. Finally, Seven Fleet Capital Management LP grew its position in shares of Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company's stock valued at $95,661,000 after buying an additional 2,425,484 shares during the last quarter. Institutional investors own 78.99% of the company's stock.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.